drugset / Trial / NCT01677884
Intra-arterial Hepatic Bevacizumab and Systemic Chemotherapy
NaSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to assessed the efficiency of treatment based on the objective response rate (RECIST 1.1)
Timeline
- Start
- 2012-11
- Primary completion
- 2016-02
- Completion
- 2016-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 7.5 mg/kg | Other |
| Subject | Capecitabine | Small molecule | 2000 mg/m2 | — |
| Subject | Irinotecan | Small molecule | 200 mg/m2 | — |
| Subject | Oxaliplatin | Small molecule | 130 mg/m2 | — |